Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/10/2017
SIETES contiene 92076 citas

 
 
 1 a 20 de 4188 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Eiden C, Mathieu O, Donnadieu-Rigole H, Marrot C, Peyrière H. High opioids tolerance due to transmucosal fentanyl abuse. Eur J Clin Pharmacol 2017;73:1195-6. [Ref.ID 102078]
2. Cita con resumen
Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf 2017;26:1083-7. [Ref.ID 102063]
3. Cita con resumen
Schuchat A, Houry D, Guy Jr GP. New data on opioid use and prescribing in the United States. JAMA 2017;318:425-6. [Ref.ID 102055]
4. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
5. Cita con resumen
Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National survey on drug use and health. Ann Intern Med 2017;167:293-301. [Ref.ID 102021]
6. Cita con resumen
Becker WC, Fiellin DA. Limited evidence, faulty reasoning, and potential for a global opioid crisis. BMJ 2017;358:j3115. [Ref.ID 102015]
8. Cita con resumen
Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]
9. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
10.Tiene citas relacionadas Cita con resumen
11. Cita con resumen
Guy Jr GP, Zhang K, Bohm MK, Lewis B, Young R, Murphy LB, Dowell D. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704. [Ref.ID 101665]
12.Tiene citas relacionadas Cita con resumen
Manhapra A, Rosenheck R. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ 2017;357:j1947. [Ref.ID 101635]
13.Tiene citas relacionadas Cita con resumen
Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. [Ref.ID 101634]
14. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
16.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
17.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
18. Cita con resumen
Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs 2017;36:1 de mayo. [Ref.ID 101570]
19. Cita con resumen
Seleccionar todas
 
 1 a 20 de 4188 siguiente >>